Molbio Diagnostics Seeks ₹940 Crore in IPO to Fuel Global Expansion

Molbio Diagnostics, a prominent player in the molecular diagnostics sector, has announced an ambitious plan to raise ₹940 crore through its initial public offering (IPO). The company aims to secure ₹200 crore via a fresh issuance of shares dedicated to capital expenditures, while an additional ₹740 crore will be generated through an offer for sale. This strategic move is expected to reduce the promoter group's stake from 46.6% to 43%.

Global Operations and Revenue Growth

Founded in 2000, Molbio Diagnostics has established a robust presence in the global diagnostics market. The company operates six manufacturing facilities across India and serves over 90 countries, including partnerships with government health programs, diagnostic laboratories, hospitals, and international healthcare organizations. A significant portion of its revenue is derived from its innovative tuberculosis diagnostic test kits, with these kits accounting for 70% of test kit sales.

Molbio's flagship product, the 'Truenat' platform, is a portable diagnostics system designed to deliver accurate results within an hour, particularly beneficial in resource-limited settings. The company offers molecular testing solutions for over 30 diseases through 43 diagnostic assays and has expanded its portfolio to include radiology, digital pathology, and breast health screening solutions through subsidiaries and strategic collaborations.

Financial Performance and Market Position

Molbio Diagnostics has demonstrated robust financial growth, with revenue from operations increasing by 31.5% annually to ₹1,445.7 crore between FY24 and FY26. The company's net profit surged by 40.2% annually to ₹164.1 crore during the same period. Its EBITDA rose by 33.2% to ₹328.2 crore, with the EBITDA margin improving to 22.6% in FY26 from 22% in FY24. On a year-on-year basis, FY26 saw a revenue increase of 41.7%, an EBITDA rise of 27.9%, and an 18.4% growth in net profit.

Despite the lack of directly comparable listed peers in India, Molbio's valuation, with a post-IPO price-earnings (P/E) multiple of up to 57, aligns it with other healthcare diagnostics and medical device firms such as Poly Medicure, Dr. Lal PathLabs, Metropolis Healthcare, and Vijaya Diagnostic Centre, which trade at P/E multiples ranging from 54 to 81.

Investor Considerations

Investors with a high-risk appetite may find Molbio Diagnostics' IPO an attractive proposition given its strong revenue streams from government and international aid agencies, which make up over four-fifths of its revenue. The company’s strategic expansion and innovative product offerings position it well for continued growth in the competitive diagnostics market.

Ultimately, Molbio Diagnostics' IPO represents a significant opportunity for investors looking to capitalize on the growing demand for advanced diagnostic solutions worldwide, offering potential long-term growth despite the inherent risks involved.